Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In its first major refresh since its establishment in 2018, the BioEscalator is delighted to welcome five leading University of Oxford academics and innovators to its Management Board. The Management Board provides a source of expertise for BioEscalator tenants and works to enhance research at the University by building strong links with small life sciences companies.

Five board members

Peter Callow is a seasoned finance executive with extensive international experience in financial management, strategic planning, and leadership.

Professor Catherine Green OBE is Head of the Clinical Biomanufacturing Facility at Nuffield Department of Medicine and Associate Professor in Chromosome Dynamics at the Centre for Human Genetics. She played a key role in developing the Oxford/AstraZeneca Covid-19 vaccine.

Professor Bethan Psaila is an Associate Professor of Haematology and Cancer Research at MRC Weatherall Institute of Molecular Medicine; she is also Co-founder of a blood malignancies company and BioEscalator tenant Alethiomics.

Professor Molly Stevens DBE is John Black Professor of Bionanoscience at the Institute of Biomedical Engineering and the Department of Physiology, Anatomy & Genetics and research director for biomedical materials at Imperial College London.

Professor Krina Zondervan is Head of the Nuffield Department of Women's & Reproductive Health, Professor of Reproductive and Genomic Epidemiology, and Co-Director of the Endometriosis Care Centre.

 

Read the full story on the BioEScalator website. 

Similar stories

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Oxford medical student takes AI safety message to the Palace of Versailles

Oxford medical student Julian Shellard has presented at an international workshop on the future of Artificial Intelligence (AI) at the Palace of Versailles in Paris, highlighting the important role medical students can play in global conversations on shaping the future of science and medicine.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group at the MRC Weatherall Institute of Molecular Medicine, have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Dunn School publishes new children’s book to mark centenary

The collaboration with Oxford University Press brings the story of the development of Penicillin to a new audience